Repurposing Gram-positive Antibiotics for Gram-Negative Bacteria using Antibiotic Adjuvants
使用抗生素佐剂重新利用革兰氏阳性抗生素治疗革兰氏阴性菌
基本信息
- 批准号:10708102
- 负责人:
- 金额:$ 73.96万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-09-20 至 2027-07-31
- 项目状态:未结题
- 来源:
- 关键词:Acinetobacter baumanniiAcuteAddressAdjuvantAdjuvant StudyAnabolismAnimalsAntibiotic ResistanceAntibioticsAreaBacteriaBacterial InfectionsBaltimoreBinding ProteinsBiogenesisBiological AssayCarbapenemsClarithromycinClinicalColistinConsensusCoupledDataDevelopmentDoseDrug InteractionsDrug KineticsEvaluationGoalsGram-Negative BacteriaHealth care facilityIn VitroInfectionIntensive Care UnitsLeadLifeLipid ALungMacrolidesMarylandMeasuresMedicalMembraneMembrane ProteinsMetabolicMetabolismMinimum Inhibitory Concentration measurementModelingMolecular TargetMulti-Drug ResistanceMultidrug-resistant AcinetobacterMultiple Bacterial Drug ResistanceO AntigensOutcomePermeabilityPharmaceutical PreparationsPlasmaPlasma ProteinsPredispositionProductionProteinsProtocols documentationPublic HealthReportingResearchResearch InstituteResistanceScourgeStructureStructure-Activity RelationshipTestingTherapeuticTissuesToxic effectUniversitiesVancomycinVirulenceWorkalternative treatmentanalogantibiotic resistant infectionsantimicrobial drugbeta-Lactamscarbapenem resistanceclinically relevantcolistin resistancecombatdesignin vitro activityin vivolead optimizationlipooligosaccharidemembermortalitymouse modelnovel strategiesnovel therapeuticsoptimal treatmentsoutcome predictionpathogenpathogenic bacteriaprogramsresistance frequencyresistance generesistance mechanismside effectsmall moleculetreatment choice
项目摘要
Multi-drug resistant (MDR) Acinetobacter baumannii infections present an enormous ongoing challenge to public
health. Due to the frequent occurrence of multidrug resistance, current treatment options for A. baumannii
infections are limited. ß-Lactam antibiotics, especially carbapenems, represent the treatment of choice for
susceptible infections. However, carbapenem resistance is increasingly common, and for such infections there
is no consensus on the optimal alternative treatment. Because resistance has hitherto been relatively
uncommon, colistin has become a favored treatment in spite of the fact that deleterious side effects are common.
However, resistance to colistin in A. baumannii is becoming more frequent with the recent dissemination of
plasmid-borne colistin resistance genes (mcr-1-10) into healthcare facilities. Unfortunately, the recent track
record of discovery of new antibiotics that are active against Gram-negative bacteria is exceedingly poor, which,
coupled with the exit of Big Pharma from antibiotic discovery, has made the development of new therapies and
non-traditional therapeutic approaches vital. To combat this growing threat, we initiated a research program to
identify small molecules, termed antibiotic adjuvants, that potentiate the activity of macrolides against MDR A.
baumannii. To this end, we have successfully identified molecules that lower the minimum inhibitory
concentration (MIC) of clarithromycin up to 512-fold against all members of a panel of primary clinical A.
baumannii isolates from the Walter Reed Army Institute of Research (WRAIR) that encompasses nearly all
clinically relevant A. baumannii clades. Adjuvants also potentiate the activity of vancomycin up to 256-fold. Both
macrolides and vancomycin are typically viewed as “Gram-positive” selective antibiotics due to their inability to
cross the outer membrane of Gram-negative bacteria, Mechanistic studies have led to a working hypothesis that
these compounds overcome this barrier by increasing permeability of the outer membrane through inhibiting
lipooligosaccharide (LOS) production. Combinations of adjuvant with clarithromycin are effective in a Galleria
mellonella model of infection, which has been shown to predict outcome in murine models of infection in the
context of MDR A. baumannii. Therefore, combinations of such adjuvants with either clarithromycin or
vancomycin may form the basis for an efficacious approach to treating MDR A. baumannii infections for which
there are no effective antibiotics.
多药耐药鲍曼不动杆菌感染对公众构成巨大的持续挑战
健康。由于多药耐药的频繁发生,目前鲍曼不动杆菌的治疗方案
感染是有限的。B-内酰胺类抗生素,特别是碳青霉烯类,代表着治疗的选择
易受感染。然而,碳青霉烯类耐药越来越普遍,对于这种感染,
对于最佳替代治疗方案,目前还没有达成共识。因为到目前为止,抵抗力相对来说
不同寻常的是,粘菌素已经成为一种受欢迎的治疗方法,尽管有害的副作用很常见。
然而,鲍曼不动杆菌对粘菌素的耐药性正在变得更加频繁,因为最近
质粒携带的粘菌素耐药基因(mcr-1-10)进入医疗机构。不幸的是,最近的曲目
发现对革兰氏阴性细菌有效的新抗生素的记录非常糟糕,
再加上大型制药公司退出抗生素发现,使得新疗法和
非传统治疗方法至关重要。为了对抗这种日益增长的威胁,我们发起了一项研究计划,以
识别被称为抗生素佐剂的小分子,它们增强大环内酯类化合物对MDR A的活性。
鲍曼尼。为此,我们已经成功地确定了降低最低抑制率的分子
克拉霉素对所有原发临床A组成员的最低抑菌浓度(MIC)高达512倍。
鲍曼氏杆菌分离自沃尔特里德陆军研究所(WRAIR),该研究所几乎涵盖了
临床相关的鲍曼假丝核菌分支。佐剂还可以增强万古霉素的活性,最高可达256倍。两者都有
大环内酯类和万古霉素通常被视为“革兰氏阳性”选择性抗生素,因为它们不能
穿过革兰氏阴性细菌的外膜,机制研究导致了一个工作假说
这些化合物通过抑制增加外膜的通透性来克服这一障碍。
脂低聚糖(LOS)生产。佐剂与克拉霉素的联合治疗在鸡冠状杆菌中有效
梅隆氏菌感染模型,已被证明可在小鼠感染模型中预测结果
鲍曼氏多药耐药菌的背景。因此,这种佐剂与克拉霉素或克拉霉素的组合
万古霉素可能成为治疗鲍曼不动杆菌多药耐药感染的有效方法的基础
目前还没有有效的抗生素。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Christian Corey Melander其他文献
Christian Corey Melander的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Christian Corey Melander', 18)}}的其他基金
Chemistry-Biochemistry-Biology Interface (CBBI) Program at Notre Dame
圣母大学化学-生物化学-生物学接口(CBBI)项目
- 批准号:
10624273 - 财政年份:2022
- 资助金额:
$ 73.96万 - 项目类别:
Repurposing Gram-positive Antibiotics for Gram-Negative Bacteria using Antibiotic Adjuvants
使用抗生素佐剂重新利用革兰氏阳性抗生素治疗革兰氏阴性菌
- 批准号:
10587015 - 财政年份:2022
- 资助金额:
$ 73.96万 - 项目类别:
Small molecule inhibitors of cariogenic biofilms
致龋生物膜小分子抑制剂
- 批准号:
10264098 - 财政年份:2020
- 资助金额:
$ 73.96万 - 项目类别:
Small molecule inhibitors of cariogenic biofilms
致龋生物膜小分子抑制剂
- 批准号:
10382468 - 财政年份:2020
- 资助金额:
$ 73.96万 - 项目类别:
Small molecule inhibitors of cariogenic biofilms
致龋生物膜小分子抑制剂
- 批准号:
10226712 - 财政年份:2020
- 资助金额:
$ 73.96万 - 项目类别:
Development of Antibiotic Adjuvants for Gram-Negative Bacteria
革兰氏阴性菌抗生素佐剂的开发
- 批准号:
10005112 - 财政年份:2018
- 资助金额:
$ 73.96万 - 项目类别:
Development of Antibiotic Adjuvants for Gram-Negative Bacteria
革兰氏阴性菌抗生素佐剂的开发
- 批准号:
9789825 - 财政年份:2018
- 资助金额:
$ 73.96万 - 项目类别:
Development of Antibiotic Adjuvants for Gram-Negative Bacteria
革兰氏阴性菌抗生素佐剂的开发
- 批准号:
10468029 - 财政年份:2018
- 资助金额:
$ 73.96万 - 项目类别:
Development of Antibiotic Adjuvants for Gram-Negative Bacteria
革兰氏阴性菌抗生素佐剂的开发
- 批准号:
10224707 - 财政年份:2018
- 资助金额:
$ 73.96万 - 项目类别:
SMALL MOLECULE INHIBITORS OF CARIOGENIC BIOFILMS
致龋生物膜的小分子抑制剂
- 批准号:
9923325 - 财政年份:2012
- 资助金额:
$ 73.96万 - 项目类别:
相似海外基金
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
- 批准号:
MR/X02329X/1 - 财政年份:2024
- 资助金额:
$ 73.96万 - 项目类别:
Fellowship
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
- 批准号:
MR/Y009568/1 - 财政年份:2024
- 资助金额:
$ 73.96万 - 项目类别:
Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
- 批准号:
10090332 - 财政年份:2024
- 资助金额:
$ 73.96万 - 项目类别:
Collaborative R&D
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
- 批准号:
MR/X021882/1 - 财政年份:2024
- 资助金额:
$ 73.96万 - 项目类别:
Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
- 批准号:
2312694 - 财政年份:2024
- 资助金额:
$ 73.96万 - 项目类别:
Standard Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
- 批准号:
EP/Y003527/1 - 财政年份:2024
- 资助金额:
$ 73.96万 - 项目类别:
Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
- 批准号:
EP/Y030338/1 - 财政年份:2024
- 资助金额:
$ 73.96万 - 项目类别:
Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
- 批准号:
MR/X029557/1 - 财政年份:2024
- 资助金额:
$ 73.96万 - 项目类别:
Research Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
- 批准号:
24K19395 - 财政年份:2024
- 资助金额:
$ 73.96万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Collaborative Research: Changes and Impact of Right Ventricle Viscoelasticity Under Acute Stress and Chronic Pulmonary Hypertension
合作研究:急性应激和慢性肺动脉高压下右心室粘弹性的变化和影响
- 批准号:
2244994 - 财政年份:2023
- 资助金额:
$ 73.96万 - 项目类别:
Standard Grant